Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease

Psychiatry Research

Volumn 207, Issue 1-2, 2013, Pages 118-126

  Labuschagne, Izelle ^a   Jones, Rebecca ^b   Callaghan, Jenny ^c   Whitehead, Daisy ^d   Dumas, Eve M ^e   Say, Miranda J ^d   Hart, Ellen P ^e   Justo, Damian ^f,g   Coleman, Allison ^h   Dar Santos, Rachelle C ^h   Frost, Chris ^b   Craufurd, David ^c   Tabrizi, Sarah J ^d   Stout, Julie C ^a  

^a MONASH UNIVERSITY   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SORBONNE UNIVERSITÉ   (France)

^g INSERM   (France)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Faces; Facial expressions; Neurodegenerative; Neuroleptic; Serotonin

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANGER; ARTICLE; CONTROLLED STUDY; DISGUST; DRUG USE; EMOTION; FACIAL EXPRESSION; FEAR; FEMALE; HAPPINESS; HUMAN; HUNTINGTON CHOREA; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; PRIORITY JOURNAL; RECOGNITION; SADNESS; TASK PERFORMANCE; VISUAL MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; EMOTIONS; FACE; FACIAL EXPRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATTERN RECOGNITION, VISUAL; PHOTIC STIMULATION; RECOGNITION (PSYCHOLOGY); SEROTONIN UPTAKE INHIBITORS;

EID: 84876881713     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.09.022     Document Type: Article

References (53)

1. Adam O.R., Jankovic J. Symptomatic treatment of huntington disease. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2008, 5:181-197.
2. Attenburrow M.J., Williams C., Odontiadis J., Reed A., Powell J., Cowen P.J., Harmer C.J. Acute administratin of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology (Berlin) 2003, 169:104-107.
3. Aviezer H., Bentin S., Hassin R.R., Meschino W.S., Kennedy J., Grewal S., Esmail S., Cohen S., Moscovitch M. Not on the face alone: perception of contextualized face expressions in Huntingtons disease. Brain 2009, 132:1633-1644.
4. Bonelli R.M., Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opinion on Pharmacotherapy 2007, 8:141-153.
5. Browning M., Reid C., Cowen P.J., Goodwin G.M., Harmer C.J. A single dose of citalopram increases fear recognition in healthy subjects. Journal of Psychopharmacology 2007, 21:684-690.
6. Calder A.J., Keane J., Young A.W., Lawrence A.D., Mason S., Barker R.A. The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia 2010, 48:2719-2729.
7. Cooney R.E., Atlas L.Y., Joormann J., Eugène F., Gotlib I.H. Amygdala activation in the processing of neutral faces in social anxiety disorder: is neutral really neutral?. Psychiatric Research: Neuroimaging 2006, 148:55-59.
8. de Gelder B., Van den Stock J., de Diego Balaguer R., Bachoud-Levi A.C. Huntington's disease impairs recognition of angry and instrumental body language. Neuropsychologia 2008, 46:369-373.
9. De Marchi N., Daniele F., Ragone M.A. Fluoxetine in the treatment of Huntington's disease. Psychopharmacology 2001, 153:264-266.
10. Delay J., Deniker P. Chlorpromazine and neuroleptic treatments in psychiatry. Journal of Clinical and Experimental Psychopathology 1956, 17:19-24.
11. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., Stout J.C., the Predict-HD Investigators Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD study. Biological Psychiatry 2007, 62:1341-1346.
12. Ekman P., Friesen W.V. Pictures of Facial Affect 1976, Consulting Psychologists Press, Palo Alto.
13. Fakra E., Khalfa S., Da Fonseca D., Besnier N., Delaveau P., Azorin J.M., Blin O. Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients. Psychopharmacology 2008, 200:261-272.
14. Fakra E., Salgado-Pineda P., Besnier N., Azorin J.M., Blin O. Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. World Journal of Biological Psychiatry 2009, 10:719-728.
15. Gray J.M., Young A.W., Barker W.A., Curtis A., Gibson D. Impaired recognition of disgust in Huntington's disease gene carriers. Brain 1997, 120:2029-2038.
16. Harmer C.J., Bhagwagar Z., Perrett D.I., Völlm B., Cowen P.J., Goodwin G.M. Acute SSRI administration affects the processing of social cues in healthy controls. Neuropsychopharmacology 2003, 28:148-152.
17. Hayes C.J., Stevenson R.J., Coltheart M. Disgust and Huntington's disease. Neuropsychologia 2007, 45:1135-1151.
18. Hayes C.J., Stevenson R.J., Coltheart M. The processing of emotion in patients with Huntington's disease: variability and differential deficits in disgust. Cognitive and Behavioral Neurology 2009, 22:249-257.
19. Heinz A., Knable M.B., Coppola R., Gorey J.G., Jones D.W., Lee K.-S., Weinberger D.R. Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophrenia Research 1998, 31:19-26.
20. Henley S.M.D., Wild E.J., Hobbs N.Z., Warren J.D., Frost C., Scahill R.I., Ridgway G.R., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia 2008, 46:2152-2160.
21. Hennenlotter A., Schroeder U., Erhard P., Haslinger B., Stahl R., Weindl A., von Einsiedel H.G., Lange K.W., Ceballos-Baumann A.O. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain 2004, 127:1446-1453.
22. Huntington Study Group Unified Huntington's Disease Rating Scale-99 1999, Huntington Study Group, Rochester, NY.
23. Johnson S.A., Stout J.C., Solomon A.C., Langbehn D.R., Aylward E.H., Cruce C.B., Ross C.A., Nance M., Kayson E., Julian-Baros E., Hayden M.R., Kieburtz K., Guttman M., Oakes D., Shoulson I., Beglinger L., Duff K., Penziner E., Paulsen J.S., the Predict-HD Investigators of the Huntington Study Group Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007, 130:1732-1744.
24. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., Knutson B., Kienast T., Gallinat J., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical neuroleptics. Psychopharmacology 2006, 187:222-228.
25. Kipps C.M., Duggins A.J., McCusker E.A., Calder A.J. Disgust and happiness recognition correlate with anteroventral insula and amygdala volume respectively in preclinical Huntington's disease. Journal of Cognitive Neuroscience 2007, 19:1206-1217.
26. Langbehn D.R., Brinkmann R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics 2004, 65:267-277.
27. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., Ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121:1329-1341.
28. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation: a longitudinal follow-up study. Journal of Neurology 2004, 251:935-942.
29. Milders M., Crawford J.R., Lamb A., Simpson S.A. Differential deficits in expression recognition in gene-carriers and patients with Huntington's disease. Neuropsychologia 2003, 41:1484-1492.
30. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. The American Journal of Psychiatry 2007, 164:630-637.
31. Montagne B., Kessels R.P., Kammers M.P., Kingma E.M., de Haan E.H., Roos R.A., Middelkoop H.A.M. Perception of emotional facial expressions at different intensities in early-symptomatic Huntington's disease. European Neurology 2006, 55:151-154.
32. Opbroek A., Delgado P.L., Laukes C., McGahuey C., Katsanis J., Moreno F.A., Manber R. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?. International Journal of Neuropsychopharmacology 2002, 5:147-151.
33. Paulsen J.S., Hayden M.R., Stout J.C., Langbehn D.R., Aylward E.H., Ross C.A., Guttman M., Nance M., Kieburtz K., Oakes D., Shoulson I., Kayson E., Johnson S.A., Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Archives of Neurology 2006, 63:883-890.
34. Penney J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Annals of Neurology 1997, 41:689-692.
35. Price C.J. The functional anatomy of word comprehension and production. Trends in Cognitive Sciences 1998, 2:281-288.
36. Savaskan E., Müller S.E., Böhringer A., Schulz A., Schachinger H. Antidepressive therapy with escitalopram improves mood, cognitive symptoms and identity memory for angry faces in elderly depressed patients. International Journal of Neuropsychopharmacology 2008, 11:381-388.
37. Schneider F., Ellgring H., Friedrick J., Fus I., Beyer T., Heimann H., Himer W. The effects of neuroleptics on facial action in schizophrenic patients. Pharmacopsychiatry 1992, 25:233-239.
38. Shoulson I., Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
39. Snowden J.S., Austin N.A., Sembi S., Thompson J.C., Craufurd D., Neary D. Emotion recognition in Huntington's disease and frontotemporal dementia. Neuropsychologia 2008, 46:2638-2649.
40. Sommers A.A. "Negative symptoms": conceptual and methodological problems. Schizophrenia Bulletin 1985, 11:364-379.
41. Sprengelmeyer R., Schroeder U., Young A.W., Epplen J.T. Disgust in pre-clinical Huntington's disease: a longitudinal study. Neuropsychologia 2006, 44:518-533.
42. Sprengelmeyer R., Young A.W., Calder A.J., Karnat A., Lange H., Homberg V., Perrett D.I., Rowland D. Loss of disgust. Perception of faces and emotions in Huntington's disease. Brain 1996, 119(Pt. 5):1647-1665.
43. Stout J.C., Jones R., Labuschagne I., O'Regan A., Say M.J., Dumas E.M., Queller S., Justo D., dar Santos R.C., Coleman A., Hart E., Dürr A., Leavitt B.R., Roos R.A.C., Langbehn D.R., Tabrizi S.J., Frost C. Evaluation of longitudinal 12- and 24-month cognitive outcomes in premanifest and early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 2012, 83:687-694.
44. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A.C., Durr A., Craufurd D., Kennard C., Hicks S.L., Fox N.C., Scahill R.I., Borowsky B., Tobin A.J., Rosas H.D., Johnson H., Reilmann R., Landwehrmeyer B., Stout J.C., TRACK-HD-Investigators Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. The Lancet Neurology 2009, 8:791-801.
45. Tabrizi S.J., Reilmann R., Roos R.A.C., Durr A., Leavitt B., Owen G., Jones R., Johnson H., Craufurd D., Hicks S.L., Kennard C., Landwehrmeyer B., Stout J.C., Borowsky B., Scahill R.I., Frost C., Langbehn D.R., the TRACK-HD investigators Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology 2012, 11:42-53.
46. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B., Jones R., Landwehrmeyer B., Fox N.C., Johnson H., Hicks S.L., Kennard C., Craufurd D., Frost C., Langbehn D., Reilmann R., Stout J.C., the TRACK-HD investigators Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology 2011, 10:31-42.
47. Tranter R., Bell D., Gutting P., Harmer C.J., Anderson I.M. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. Journal of Affective Disorders 2009, 118:87-93.
48. UNESCO International Standard Classification of Education, 1997. (accessed 16 Nov 2007). http://www.uis.unesco.org.
49. van Duijn E. Treatment of irritability in Huntington's disease. Current Treatment Options in Neurology 2010, 12:424-433.
50. Wang K., Hoosain R., Yang R.M., Meng Y., Wang C.Q. Impairment of recognition of disgust in Chinese with Huntington's or Wilson's disease. Neuropsychologia 2003, 41:527-537.
51. Whitaker R. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Medical Hypotheses 2004, 62:5-13.
52. Williams L.M., Loughland C.M., Green M.J., Harris A.W.F., Gordon E. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatric Research 2003, 120:13-27.
53. Winton E.C., Clark D.M., Edelmann R.J. Social anxiety, fear of negative evaluation and the detection of negative emotion in others. Behaviour Research and Therapy 1995, 33:193-196.